NVO vs. NVS: Novo Nordisk vs. Novartis Stock Comparison

Company Profile

Novo Nordisk (NVO) and Novartis (NVS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Both Novo Nordisk (NVO) and Novartis (NVS) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Novo Nordisk (NVO) at 71.40% and Novartis (NVS) at 34.93% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Novo Nordisk (NVO) at 37.21% and Novartis (NVS) at 23.92% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Novo Nordisk (NVO) at 61.57% and Novartis (NVS) at 30.48% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Novo Nordisk (NVO) at 6.43% and Novartis (NVS) at 9.57% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Novo Nordisk (NVO) at 1.77% and Novartis (NVS) at 21.81% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Novo Nordisk (NVO) at 0.79 and Novartis (NVS) at 0.85 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Novo Nordisk (NVO) at 0.72 and Novartis (NVS) at 1.21 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Novartis (NVS) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 23.58%, ranking against industry peers normally.

Both Novo Nordisk (NVO) at 42.59% and Novartis (NVS) at 67.91% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 11.90 sits in the cheaper P/E ratio quartile, while Novartis (NVS) at 21.40 is closer to its industry’s usual earnings multiple — a discount for NVO, though growth and earnings durability still matter.

Novo Nordisk (NVO) at 0.67 sits in the cheaper P/S ratio quartile while Novartis (NVS) at 5.17 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

Novo Nordisk (NVO) at 7.08 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 7.62 carries an above-peer premium to book — NVS is pricier on assets.

Valuation Metrics